Natalie Sacks
Directeur/Membre du Conseil chez CARIBOU BIOSCIENCES, INC.
Fortune : 104 951 $ au 30/04/2024
Postes actifs de Natalie Sacks
Sociétés | Poste | Début | Fin |
---|---|---|---|
CARIBOU BIOSCIENCES, INC. | Directeur/Membre du Conseil | 01/05/2018 | - |
Independent Dir/Board Member | 01/05/2018 | - | |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Directeur/Membre du Conseil | 01/04/2020 | - |
Historique de carrière de Natalie Sacks
Anciens postes connus de Natalie Sacks
Sociétés | Poste | Début | Fin |
---|---|---|---|
ZYMEWORKS INC. | Directeur/Membre du Conseil | 01/08/2017 | 30/06/2023 |
HARPOON THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/10/2018 | 01/06/2022 |
CHINOOK THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 06/09/2016 | 01/09/2018 |
The University of California, San Francisco | Corporate Officer/Principal | 01/01/2003 | 01/01/2016 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Directeur Technique/Scientifique/R&D | 01/01/2011 | 01/01/2014 |
EXELIXIS, INC. | Directeur Technique/Scientifique/R&D | 01/09/2009 | 01/03/2011 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Directeur Technique/Scientifique/R&D | 01/11/2002 | 01/04/2009 |
░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | - | - |
Formation de Natalie Sacks
Bryn Mawr College | Undergraduate Degree |
Harvard T.H. Chan School of Public Health | Graduate Degree |
Perelman School of Medicine | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 12 |
Canada | 2 |
Danemark | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 5 |
Director/Board Member | 4 |
Independent Dir/Board Member | 2 |
Sectorielle
Health Technology | 10 |
Consumer Services | 5 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 4 |
---|---|
EXELIXIS, INC. | Health Technology |
CARIBOU BIOSCIENCES, INC. | Health Technology |
HARPOON THERAPEUTICS, INC. | Health Technology |
ZYMEWORKS INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Aduro BioTech, Inc.
Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
STipe Therapeutics ApS
STipe Therapeutics ApS Pharmaceuticals: MajorHealth Technology STipe Therapeutics ApS operates as a biotechnology company. It specializes in the immune-oncology field, pioneer therapies using a novel aspect of the stimulator of interferon genes (STING) Pathway to target cancer. The company was founded in 2018 and is headquartered in Denmark. | Health Technology |
- Bourse
- Insiders
- Natalie Sacks
- Expérience